MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fphar.2026.1924307

Медицинская библиотека · Frontiers in pharmacology · 2026

A microdose cocktail and population pharmacokinetic study suggests potentially reduced CYP3A and P-gp activities in type 2 diabetes.

Li Yafen, Yang Jin, Zhou Enda, Geng Kuo, Lei Zihan, Yao Xueting, Feng Feifei, Jin Yuyan, Kong Weijie, Hu Yiyi, Liang Hao, Li Haiyan, Yang Guo-Ping, Hong Tianpei, Liu Dongyang

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Diabetes patients often exhibit suboptimal efficacy and adverse reactions, accompanied by pharmacokinetic (PK) changes, indicating drug-metabolizing enzymes and transporters (DMET) activities may change. This study aimed to determine whether type 2 diabetes affects DMET activities and quantify impact magnitude. Furthermore, gut microbiome, pharmacogenetic and demographic characteristics were assessed to elucidate the sources of inter-individual variability (IIV) in DMET activities.

METHODS

The activities of CYP3A and transporters P-gp, OATP and BCRP were evaluated in type 2 diabetes patients and healthy volunteers (HVs) following a single oral dose of five probe drugs (midazolam, dabigatran etexilate, pitavastatin, rosuvastatin, and atorvastatin). Population pharmacokinetics (PopPK) and an exploratory machine learning (ML) analysis were employed to quantify the impact of type 2 diabetes on DMET activities.

RESULTS

Based on observed PK parameters, compared to HVs, type 2 diabetes patients exhibited increased exposure to midazolam (1.38-fold), dabigatran (1.40-fold), and atorvastatin (1.93-fold), whereas pitavastatin (0.931-fold) and rosuvastatin (1.25-fold) showed no change. PopPK analysis revealed that the mean activities of CYP3A and P-gp were potentially decreased by 23% and 27%, respectively, in type 2 diabetes patients, while no changes for OATP and BCRP. Notably, unlike the direct patient population covariate for P-gp, reduced CYP3A activity was indirectly estimated from lower Salmonella abundance. Additionally, factors such as sex, BCRP genotype, and Clostridium_XlVb partly explained the IIV in probe drugs exposure.

CONCLUSION

The findings regarding altered DMET activities and identified influence factors help to identify specific drug classes that may warrant closer clinical attention in type 2 diabetes patients.

Для цитирования: Li Yafen, Yang Jin, Zhou Enda, Geng Kuo, Lei Zihan, Yao Xueting, Feng Feifei, Jin Yuyan, Kong Weijie, Hu Yiyi, Liang Hao, Li Haiyan, Yang Guo-Ping, Hong Tianpei, Liu Dongyang. A microdose cocktail and population pharmacokinetic study suggests potentially reduced CYP3A and P-gp activities in type 2 diabetes.. Frontiers in pharmacology. 2026. DOI: 10.3389/fphar.2026.1924307.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.